Drug intelligence / Profile preview

Compound 26

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

Compound 26, also known as MMP118, is a potent and selective small molecule inhibitor of matrix metalloproteinase-12 (MMP-12). It is being developed for the potential treatment of chronic obstructive pulmonary disease (COPD) and asthma. MMP-12 is a key proteolytic enzyme implicated in airway remodeling, elastin destruction, and aberrant remodeling of damaged alveoli in these inflammatory lung diseases. Compound 26 has demonstrated excellent oral efficacy in mouse models of MMP-12 induced ear-swelling inflammation and lung inflammation.

Targets

MMP12 (Macrophage Metalloelastase)

Beyond the preview

Go deeper on Compound 26.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Compound 26.

Explore the full profile